This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Albinism / Oculocutaneous Albinism OCA1–4 / Ocular Albinism OA1백색증 (눈피부백색증 · 눈백색증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E70.3 (Albinism; same code as Cross syndrome and Chédiak-Higashi, but separate file) | OMIM: 203100 (OCA1A), 606952 (OCA2), 203290 (OCA3), 606574 (OCA4), 300500 (OA1) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsOculocutaneous albinism (OCA; OCA1A, OCA1B, OCA2, OCA3, OCA4), ocular albinism (OA; OA1 / Nettleship-Falls type), generalized albinism, tyrosinase-negative albinism (OCA1A), yellow albinism (OCA1B)
C. Adult onsetPossibility of first presentation in adulthood: none (congenital) — albinism is a congenital disease in which pigment deficiency is present from birth; however, in mild forms such as OCA1B, pigment may partially increase with age, and complications such as skin cancer and reduced vision may first become problems in adulthood.
1. HistoryRecorded even in ancient Egyptian and Roman texts → 1842: Pearson's clinical description of OCA → 1952: tyrosinase deficiency hypothesis proposed → 1986: TYR gene cloned → 1994–2002: OCA2, 3, and 4 genes identified → 2001: X-linked OA1 (GPR143) identified.
2. CausesOCA1: TYR gene (11q14.3) variants → deficiency of tyrosinase (key enzyme of melanin synthesis). OCA2: OCA2 gene (15q13.1) → P-protein deficiency. OCA3: TYRP1 (9p23) → tyrosinase-related protein 1 deficiency. OCA4: SLC45A2 (5p13.2) → MATP deficiency. OA1 (X-linked): GPR143 (Xp22.2) → abnormal melanosome maturation.
3. GeneticsOCA1–4: autosomal recessive. OA1: X-linked recessive (female carriers may have pigment abnormalities). In Korea and Japan, OCA4 (SLC45A2) variants are known to be the most common OCA type. OCA2 is the most common type in Black Africans.
4. General epidemiologyOverall incidence of OCA approx. 1:17,000 (highest in sub-Saharan Africa, 1:3,000–1:5,000). Incidence of OCA1 in white populations approx. 1:40,000. OCA4 is the most common type in East Asia (a substantial proportion of OCA patients in Korea and Japan). OA1: 1:50,000 (males).
5. PathophysiologyMelanocytes are present, but melanin synthesis or melanosome maturation is impaired → pigment deficiency of skin, hair, and iris + pigment deficiency of the retinal pigment epithelium (RPE) → abnormal development of the optic pathways (excessive decussation) → reduced visual acuity, nystagmus, loss of stereopsis. No skin pigment → increased risk of UV damage and skin cancer.
6. SymptomsPigment deficiency (skin, hair, iris; completely absent in OCA1A, partial in others). Reduced visual acuity (mainly around 0.1–0.3; partially correctable with glasses). Nystagmus. Photophobia. Strabismus. Foveal hypoplasia. Increased risk of sunburn and skin cancer (melanoma, squamous cell carcinoma).
7. SignsTranslucent iris (light transmission). Red pupillary reflex (fundus reflex). Nystagmus (bilateral, horizontal or mixed). Foveal hypoplasia (OCT). Abnormal optic chiasm decussation (VEP asymmetry). Reduced skin and hair pigment (completely white in OCA1A, variable in OCA2, 3, 4). UV-damaged skin lesions.
8. ScreeningNot a target of newborn screening. Clinical diagnosis (pigment deficiency observed at birth). Ophthalmological examination (nystagmus, iris pigment, foveal hypoplasia, VEP). Hair bulb tyrosinase activity test (distinguishing OCA1A vs. 1B, adjunctive). Molecular genetic testing (TYR, OCA2, TYRP1, SLC45A2, GPR143 NGS panel).
9. DiagnosisClinical diagnosis (pigment deficiency + nystagmus + foveal hypoplasia). Ophthalmology: slit lamp (iris transillumination), fundus examination (foveal hypoplasia), OCT (retinal structure), VEP (abnormal decussation ratio). Dermatology: reflectance meter (quantification of skin pigment). Molecular genetics: TYR/OCA2/TYRP1/SLC45A2/GPR143 panel NGS or single gene. Electron microscopy (hair melanosome morphology, for research purposes).
10. TreatmentCurrently no curative treatment. Eyes: corrective lenses (glasses, contact lenses), prism glasses (nystagmus dampening), low-vision aids. Strabismus surgery. Skin: sunscreen (SPF 50+), protective clothing. Regular dermatological checkups (early detection of skin cancer). Pigment cell transplantation (research stage). Gene therapy (OA1, research stage). Low-vision educational support.
11. PrognosisNormal life expectancy. Normal intellectual ability. Vision: OCA1A most severe (corrected 0.05–0.1), OCA1B, 2, 3, 4 mild to moderate (corrected 0.1–0.4). Nystagmus partially decreases in adulthood. Main mortality risk: high risk of early death from skin cancer (squamous cell carcinoma, melanoma) in regions with strong sunlight, such as Africa.
12. PreventionPrimary: genetic counseling, family genetic testing, prenatal diagnosis (by OCA subtype). Secondary: clinical diagnosis and ophthalmological evaluation immediately after birth, start of UV protection education. Tertiary: regular ophthalmological and dermatological follow-up, continued skin protection, use of low-vision aids, school and vocational support, psychological and social support.
13. ReferencesOetting WS, King RA. Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum Mutat. 1999. and 9 other papers

1. History

Albinism is one of the longest-recorded genetic diseases in human history. Descriptions of people lacking skin and hair pigment appear even in ancient Egyptian papyri and Roman-era texts, and people with albinism are believed to have been depicted in various artworks of the medieval and early modern periods. People with albinism whom European explorers first encountered in Africa, the Americas, and Asia were at the time sometimes called 'moon children' or 'White Moors.'

The modern medical description began in 1842 when Pearson et al. systematically described the clinical features of oculocutaneous albinism (OCA). In 1902, Archibald Garrod classified albinism, together with alkaptonuria, as one of the "inborn errors of metabolism." In 1952, Meyer-Gross et al. proposed that deficiency of tyrosinase enzyme activity is the main cause of OCA.

With advances in molecular genetics, in 1986 the TYR (tyrosinase) gene was cloned on the long arm of chromosome 11 (11q14.3), confirming that the molecular cause of OCA1 is tyrosinase gene variants. Subsequently, the gene causing OCA2 (OCA2, 15q13.1) was identified in 1994, the TYRP1 (tyrosinase-related protein 1) gene as the cause of OCA3 in 1998, and the SLC45A2 (solute carrier family 45, member 2) gene as the cause of OCA4 in 2003. GPR143 (G-protein coupled receptor 143, Xp22.2), the causative gene of ocular albinism (OA1), was identified in 2001.

Molecular genetic studies have shown that in East Asia, including Korea, OCA4 (SLC45A2 gene variants) is the most common OCA type. In a Japanese study, more than about 50% of OCA patients had SLC45A2 variants, and a similar trend has been reported in Korea. This is an East Asia-specific distribution, in contrast to the West, where OCA1 is the most common.

Since the 2010s, additional genotypes including OCA5–8 have been identified, and to date more than 20 genes are known to cause various forms of hypopigmentation. Researchers are currently actively studying gene therapy (particularly AAV-based retinal gene therapy for OA1) and pigment cell transplantation techniques.


2. Causes

Albinism is a group of hereditary pigment-deficiency disorders caused by pathogenic variants in genes involved in melanin synthesis or melanosome maturation. Melanocytes are distributed in the skin, hair follicles, retinal pigment epithelium (RPE), iris, inner ear, and elsewhere, and deficiency of enzymes and transport proteins involved in melanin synthesis leads to absent or reduced pigment. The causative genes and mechanisms of the main types are as follows.

Oculocutaneous albinism type 1 (OCA1, OMIM 203100): TYR gene (11q14.3) variants → deficiency of the tyrosinase (TYR) enzyme. Tyrosinase is the key enzyme of melanin synthesis, catalyzing the oxidation of tyrosine to DOPA (3,4-dihydroxyphenylalanine) and of DOPA to dopaquinone. OCA1A (complete tyrosinase deficiency): no enzyme activity → melanin synthesis completely impossible → completely white skin, hair, and iris. OCA1B (residual tyrosinase activity): some enzyme activity remains → white skin at birth, but some pigment may accumulate with age → also called 'yellow albinism.'

Oculocutaneous albinism type 2 (OCA2, OMIM 606952): OCA2 gene (15q13.1) variants → P-protein deficiency. The P-protein is an ion transport protein of the melanosome membrane involved in regulating intramelanosomal pH and is needed to optimize tyrosinase activity. It is the most common type in sub-Saharan Africa.

Oculocutaneous albinism type 3 (OCA3, OMIM 203290): TYRP1 gene (9p23) variants → tyrosinase-related protein 1 (TYRP1) deficiency. TYRP1 is an enzyme that contributes to the stability of tyrosinase, and this type is reported mainly in people of African descent (also known as 'rufous OCA,' characterized by reddish skin and hair).

Oculocutaneous albinism type 4 (OCA4, OMIM 606574): SLC45A2 gene (5p13.2) variants → MATP (membrane-associated transporter protein) deficiency. MATP is a transport protein in the melanosome membrane involved in supplying melanin synthesis substrates into the melanosome. It is the most common OCA type in East Asia (Korea, Japan, China).

Ocular albinism type 1 (OA1, OMIM 300500, X-linked): GPR143 gene (Xp22.2) variants → G protein-coupled receptor 143 (GPR143) deficiency. Skin and hair pigmentation are near normal, but ocular symptoms (nystagmus, foveal hypoplasia, reduced visual acuity) predominate due to abnormal melanosome maturation in the retinal pigment epithelium. Because it is X-linked recessive, it is mainly expressed in males, and iris pigment abnormalities may be observed in female carriers.


3. Genetics

OCA1–4 all follow autosomal recessive inheritance and are expressed only when pathogenic variants are present in both alleles. OA1 follows X-linked recessive inheritance and is mainly expressed in males (hemizygotes).

TYR gene (OCA1): OMIM *606933, 11q14.3, 5 exons. More than 300 pathogenic variants have been reported worldwide, with missense variants the most common (approx. 60%). Variants are divided into those causing complete loss of enzyme activity (OCA1A) and those with residual activity (OCA1B). Main variants: p.Pro406Leu (common in OCA1B), c.1037-7T>A (IVS2-7T>A splicing, reported in Korea and Japan).

OCA2 gene (OCA2): OMIM *611409, 15q13.1, 24 exons. Most common in sub-Saharan Africa, and a 2.7 kb deletion founder variant is known in patients of African descent. OCA2 variants are also reported in East Asian patients but are rarer than OCA4.

SLC45A2 gene (OCA4): OMIM *606547, 5p13.2, 7 exons. The most common causative gene in East Asian OCA patients. Studies indicate that the proportion of SLC45A2 variants found in OCA in Korean and Japanese patients is higher than that of TYR variants in Western patients. There are also reports that OCA4 variants outnumber OCA1 variants among Han Chinese.

GPR143 gene (OA1): OMIM *300808, Xp22.2, 9 exons. X-linked recessive inheritance. In female carriers, abnormal size of skin melanocytes and partial iris pigment abnormalities (mud splatter appearance) may be observed. The complete OA1 phenotype appears only in males.

In genetic counseling, for recessive OCA subtypes the recurrence risk for children of carrier parents is 25%; for OA1, there is a risk from a carrier mother of 50% for sons and 50% for daughters (50% of daughters being carriers). In East Asia, a sequential approach is efficient when diagnosing OCA4: perform SLC45A2 gene testing first, and if negative, expand to TYR and OCA2 testing.


4. General epidemiology

The worldwide incidence of albinism differs markedly by type and region. The worldwide average incidence of OCA overall is estimated at approximately 1:17,000, but regional variation is large. In sub-Saharan Africa, OCA2 is the most common, with an incidence of 1:3,000–1:5,000, the highest in the world. Even higher incidences are reported in some areas of Tanzania and Nigeria. In Europe and North America, OCA1 is the most common, with an incidence of approximately 1:40,000.

In East Asia (Korea, Japan, China), OCA4 (SLC45A2 variants) is known to be the most common OCA type. In a molecular epidemiological study conducted in Japan, SLC45A2 variants were identified in approximately 50–60% of OCA patients. A similar trend is reported in Korea, but systematic incidence data are lacking. The incidence of ocular albinism (OA1) is reported at approximately 1:50,000 in males.

In terms of sex distribution, OCA1–4 affect males and females equally, but OA1, being X-linked recessive, shows the complete phenotype only in males. Albinism occurs in all races, but the predominant genotype differs by race. In blond, blue-eyed Northern Europeans who already have little pigment, clinical distinction from albinism can be difficult, but it is confirmed by foveal hypoplasia, nystagmus, and VEP abnormalities.

From a public health perspective, in sub-Saharan Africa, people with albinism have a risk of skin cancer (squamous cell carcinoma, basal cell carcinoma, melanoma) from intense UV exposure that is hundreds to thousands of times higher than that of the general population, and resulting premature death is a major problem. In this region, albinism has become an important public health issue beyond a simple rare genetic disease, and the risk of social discrimination and violence also links it to human rights issues.


5. Pathophysiology

The key to understanding the pathogenesis of albinism is how a defect at a specific step of the melanin biosynthesis pathway leads to combined abnormalities of the skin, eyes, and nervous system.

Impaired melanin synthesis: melanocytes synthesize melanin in specialized organelles called melanosomes. In the pathway tyrosine → DOPA → dopaquinone → eumelanin or pheomelanin, tyrosinase (TYR) acts as the rate-limiting enzyme. Deficiency of TYR (OCA1) or of proteins that support the melanosomal environment for TYR activity (pH regulation, substrate supply) (the P-protein in OCA2, MATP in OCA4) blocks or greatly reduces melanin synthesis. Melanocytes themselves develop and migrate normally and are present in tissues, but cannot produce melanin.

Abnormal retinal and optic nerve development: the effect of melanin on retinal development is particularly important. During fetal development, melanin in the retinal pigment epithelium (RPE) is needed for formation of the fovea and for regulating the normal decussation ratio of optic nerve axons. RPE pigment deficiency interferes with normal formation of the foveal pit, resulting in foveal hypoplasia. Foveal hypoplasia is the direct cause of reduced central visual acuity. In addition, the proportion of uncrossed fibers at the optic chiasm is reduced below normal, so most optic nerve fibers cross to the opposite hemisphere. This abnormal decussation pattern appears as a specific asymmetry on visual evoked potentials (VEP), and the mismatch of binocular visual fields results in impaired stereopsis and abnormal binocular interaction.

Nystagmus: defective visual feedback due to foveal hypoplasia and abnormal optic pathways causes abnormalities in the oculomotor control circuits, resulting in irregular nystagmus. Nystagmus begins to appear 2–3 months after birth and prevents fixation of central vision, further impairing visual development.

Skin vulnerability: melanin absorbs ultraviolet radiation (especially UVB) and protects the skin from oxidative stress. Melanin deficiency accelerates UV damage, DNA double-strand breaks, and skin aging, and markedly increases the risk of skin cancer (squamous cell carcinoma, basal cell carcinoma, melanoma).


6. Symptoms

The main symptoms of albinism are pigment deficiency and visual system abnormalities. The severity of symptoms varies with genotype and residual melanin synthesis capacity.

Pigment deficiency: OCA1A (complete tyrosinase deficiency): there is no melanin at all in the skin, hair, and iris, so the skin is white, the hair is white, and the iris is pink to red (showing through of blood vessels). OCA1B, OCA2, OCA3, OCA4: pigment is very scant at birth but may partially increase with age. Hair may be yellow to light brown and the iris blue to light brown. OA1: skin and hair pigment is normal to mildly reduced, and ocular abnormalities are the main symptoms.

Visual abnormalities: reduced visual acuity is common. It is most severe in OCA1A, where corrected visual acuity often remains around 0.05–0.1. In other types as well, corrected visual acuity is around 0.1–0.4, corresponding to legal low vision. Horizontal nystagmus appears in most patients, accompanied by photophobia (hypersensitivity to bright light) and tearing. Strabismus (exotropia or esotropia) is common, and stereopsis is lost.

Skin vulnerability: patients are extremely vulnerable to sunburn, and chronic sun exposure can lead to actinic keratosis, squamous cell carcinoma, and basal cell carcinoma. Melanoma is rare but can occur.

Psychosocial impact: social stigma due to differences in appearance, discrimination at school and work, and learning difficulties due to low vision can cause psychosocial problems.


7. Signs

The objective signs of albinism are confirmed through clinical examination, ophthalmological examination, and electrophysiological testing.

Iris transillumination: on slit-lamp examination, when light is passed through the iris, it is transmitted because of pigment deficiency (positive transillumination). Complete transillumination in OCA1A, partial transillumination in other types. Generalized iris transillumination is observed in male OA1 patients.

Foveal hypoplasia: fundus examination and OCT (optical coherence tomography) show loss or reduction of the foveal pit and increased normal macular refraction (reduced foveal avascular zone). This is the direct morphological basis for reduced central visual acuity.

Visual evoked potential (VEP) asymmetry: on monocular stimulation, an asymmetric finding in which the VEP waveform is larger over the contralateral hemisphere (contralateral VEP predominance) is a specific electrophysiological marker of albinism. It is the electrophysiological reflection of abnormal optic chiasm decussation.

Nystagmus: horizontal nystagmus is most common, in pendular or jerk form. It appears from 2–3 months of age. In some patients, nystagmus partially decreases in adulthood.

Skin findings: reduced pigment is quantitatively confirmed with a skin pigment reflectance meter (spectrophotometry, ITA value). UV damage, actinic keratosis, and skin tumors may be observed in adulthood.


8. Screening

Albinism is not a target of standard newborn screening (neonatal DBS MS/MS). Tyrosine levels are generally normal, and there is no specific screening biomarker. Therefore, clinical observation immediately after birth and specialized ophthalmological examination are key to early diagnosis.

Clinical diagnostic clues: the first clue is observation of reduced skin and hair pigment by parents or medical staff at birth. In particular, when the parents' pigmentation is normal, reduced pigmentation in a newborn should immediately raise suspicion of a genetic disorder. In OA1, skin and hair are near normal, making it difficult to suspect a pigment abnormality, and it is often found after referral to ophthalmology at 2–3 months of age or later, when nystagmus appears.

Ophthalmological screening: when nystagmus, photophobia, or poor visual fixation is observed in a neonate or infant, refer immediately to an ophthalmologist. Slit-lamp examination (iris transillumination) and fundus examination (presence of foveal hypoplasia) are key. At 6–9 months of age, VEP testing confirms abnormal optic chiasm decussation.

Family screening: in families with a sibling with OCA, immediate ophthalmological evaluation and molecular genetic testing of the newborn are recommended. Prenatal diagnosis is possible in families with a known gene variant.

Differential diagnosis: differentiation is needed from Prader-Willi syndrome (reduced pigmentation similar to albinism), Angelman syndrome (overlap of the OCA2 location with 15q11-q13), Hermansky-Pudlak syndrome (OCA with platelet abnormalities), and Chédiak-Higashi syndrome (OCA with immune abnormalities).


9. Diagnosis

Confirmation of albinism is made by a combination of clinical findings, ophthalmological examination, and molecular genetic testing.

Clinical diagnosis (confirming pigment deficiency): skin pigment is quantified with a skin reflectance meter (ITA: individual typology angle). Assessment of hair and iris pigment. OCA1A: complete absence of pigment in skin, hair, and iris. OCA1B, 2, 3, 4: partial pigment reduction (variable). OA1: skin and hair nearly normal, ocular abnormalities predominant.

Ophthalmological examination: slit-lamp examination (iris transillumination). Indirect ophthalmoscopy (foveal hypoplasia, presence of optic disc pallor). OCT (loss of the foveal pit, macular thickness map). Visual acuity measurement (distance and near corrected visual acuity). Refractive error testing (myopia, hyperopia, astigmatism). Nystagmus measurement (video-oculography). VEP (visual evoked potentials: confirming the asymmetric decussation pattern).

Molecular genetic testing: in East Asian patients, SLC45A2 single-gene testing first (OCA4 is the most frequent); if negative, an expanded panel including TYR, OCA2, TYRP1, and GPR143, or a full OCA panel by NGS. Molecular confirmation is essential for genetic counseling, prenatal diagnosis, and carrier testing.

Hair bulb tyrosinase assay: DOPA reaction positive (able to convert DOPA to melanin) = OCA1B, OCA2, OCA4, etc. Negative = OCA1A (complete tyrosinase deficiency). It is now being replaced by molecular testing but can be useful as an adjunct.

Tests to exclude associated syndromes: complete blood count and platelet function tests (Hermansky-Pudlak), peripheral blood smear (identification of giant granules in Chédiak-Higashi), neurological evaluation, etc.


10. Treatment

There is currently no curative treatment for albinism, and most treatment focuses on symptom management and prevention of complications.

Ophthalmological treatment: prescribing corrective lenses for refractive errors (myopia, hyperopia, astigmatism; astigmatism is particularly important) is the first priority. Maximum corrected visual acuity is achieved with glasses or soft/hard contact lenses. Tinted or UV-blocking lenses are used to relieve photophobia. Prism glasses for nystagmus are useful in some patients to exploit the nystagmus null point. Strabismus surgery: correction of nystagmus-associated head tilt or strabismus surgery for cosmetic purposes. Low-vision aids: magnifiers, telescopic lenses, electronic magnifiers, screen magnification software.

Skin protection: use of SPF 50+ broad-spectrum sunscreen (UVA/UVB) every day, year-round is essential. Avoid outdoor activities during hours of strong UV (10 a.m.–4 p.m.) as much as possible. UV-protective clothing (UPF 50+ certified), wide-brimmed hats, UV-blocking glasses. Lip protection (UV-blocking lip balm). Regular dermatological checkups (at least once a year, for early detection of skin cancer).

Educational and vocational support: adaptation of the educational environment for low vision (large-print materials, magnification programs, front-row seating, lighting adjustment). Vocational counseling and support for choosing low-vision-friendly occupations. Driving ability assessment (most OCA1A patients do not meet the legal vision standard).

Treatments at the research stage: AAV8-mediated retinal gene therapy for OA1 has shown improvement in retinal pigmentation and visual acuity in animal studies, and clinical trials are under way. Pigment cell transplantation (melanocyte transplantation) is also at the research stage. mRNA-based TYR gene therapy is also in preclinical research.


11. Prognosis

The life expectancy of people with albinism is not shortened by the pigment deficiency itself, and intellectual ability and cognitive function are normal. The main prognostic determinants are visual acuity, skin complications, and living environment (sunlight exposure).

Visual acuity: visual impairment is most severe in OCA1A, where maximum corrected visual acuity remains at 0.05–0.1, greatly limiting learning and driving. In OCA1B, OCA2, OCA3, and OCA4, corrected visual acuity is better, around 0.1–0.4; daily functioning is affected, but independent living is possible. Nystagmus sometimes decreases partially and spontaneously in adulthood. Foveal hypoplasia itself is not improved by current treatment.

Skin complications: in people with albinism living in regions with strong UV radiation (sub-Saharan Africa, tropical and subtropical regions), skin cancer (especially squamous cell carcinoma) is a major cause of death and often occurs at an early age, in the 40s–50s. In patients who practice thorough UV protection, the risk of skin cancer is markedly reduced. In regions with relatively little sunlight, such as Korea, the risk of skin cancer is relatively lower, but UV protection is still essential.

Psychosocial prognosis: social stress due to differences in appearance, academic and occupational limitations due to low vision, and reduced self-esteem affect quality of life. Patient support groups and psychological support services are important.


12. Prevention

Prevention strategies for albinism consist of three levels: genetic prevention, early diagnosis, and management of complications.

Primary prevention: genetic counseling and carrier testing for families of confirmed patients. Prenatal genetic diagnosis (testing for the causative gene through chorionic villus sampling or amniocentesis) or PGT-M for carrier parents. However, considering that albinism is currently not an untreatable disease (it is a manageable condition), careful discussion of the ethical aspects of prenatal diagnosis is needed.

Secondary prevention (early diagnosis): pigment deficiency is detected at birth or within the first few weeks of life, prompting immediate ophthalmological evaluation and the establishment of a confirmatory diagnosis and visual rehabilitation plan. Because OA1 may be detected late owing to near-normal pigmentation, albinism must always be included in the differential diagnosis of infants presenting with nystagmus or strabismus.

Tertiary prevention (minimizing complications): lifelong UV protection (SPF 50+ sunscreen, protective clothing, UV-blocking glasses). Regular dermatological checkups (at least once a year, for early detection of skin lesions). Regular ophthalmological follow-up (monitoring changes in nystagmus, strabismus, refractive errors). Low-vision aids and educational support. Psychological and social support and connection with patient organizations.


13. References

  1. Oetting WS, King RA. Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum Mutat. 1999;13(2):99-115. DOI
  2. Grønskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. Orphanet J Rare Dis. 2007;2:43. DOI: 10.1186/1750-1172-2-43
  3. Montoliu L, Grønskov K, Wei AH, et al. Increasing the complexity: new genes and new types of albinism. Pigment Cell Melanoma Res. 2014;27(1):11-18. DOI: 10.1111/pcmr.12167
  4. Simeonov DR, Wang X, Wang C, et al. DNA variations in oculocutaneous albinism: an updated mutation list and current outstanding issues in molecular genetics. Hum Mutat. 2013;34(6):827-835. DOI: 10.1002/humu.22315
  5. Käsmann-Kellner B, Weindler J, Pfau B, et al. Ocular changes in albinism and their morphological correlations to visual functions. Graefes Arch Clin Exp Ophthalmol. 1999;237(12):969-974. DOI: 10.1007/s004170050343
  6. Lee ST, Nicholls RD, Bundey S, et al. Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome plus albinism. N Engl J Med. 1994;330(8):529-534. DOI: 10.1056/NEJM199402243300803
  7. Inagaki K, Suzuki T, Shimizu H, et al. Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. Am J Hum Genet. 2004;74(3):466-471. DOI: 10.1086/382195
  8. Thomas MG, Papageorgiou E, Kuht HJ, Gottlob I. Normal and abnormal foveal development. Br J Ophthalmol. 2022;106(5):593-599. DOI: 10.1136/bjophthalmol-2021-319371
  9. Lund PM, Maluleke TG, Gaigher I, Gaigher MJ. Oculocutaneous albinism in a rural community of South Africa: a population genetic study. Ann Hum Biol. 2007;34(4):493-497. DOI: 10.1080/03014460701401081
  10. Tanimoto N, Sothilingam V, Seeliger MW. Pathophysiology of retinal dystrophy and degeneration: from genetics to mechanisms. Prog Retin Eye Res. 2022;89:101034. DOI: 10.1016/j.preteyeres.2021.101034